Cytek Biosciences, Inc. (CTKB) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $4.07 (+3.31%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 2, 2025 | Matthew Sykes | Goldman Sachs | $5.25 | +29.2% |
| May 13, 2024 | Dave Westenberg | Piper Sandler | $8.50 | +109.1% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $16.00 | +293.6% |
| May 15, 2022 | David Westenberg | Piper Sandler | $12.00 | +195.2% |
Top Analysts Covering CTKB
CTKB vs Sector & Market
| Metric | CTKB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.24 | 2.40 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +29.7% | +11475.0% | +17.1% |
| P/E Ratio | -8.80 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $208M | $208M | $209M | 4 |
| 2027-03-31 | $45M | $47M | $49M | 1 |
| 2027-06-30 | $50M | $52M | $54M | 2 |
| 2027-09-30 | $58M | $60M | $62M | 2 |
| 2027-12-31 | $63M | $65M | $67M | 1 |
| 2028-03-31 | $50M | $52M | $54M | 1 |
| 2028-06-30 | $54M | $56M | $58M | 1 |
| 2028-09-30 | $65M | $67M | $70M | 1 |
| 2028-12-31 | $69M | $72M | $74M | 1 |
| 2029-12-31 | $256M | $259M | $260M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.30 | $-0.21 | $-0.09 | 2 |
| 2027-03-31 | $-0.08 | $-0.07 | $-0.07 | 1 |
| 2027-06-30 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2027-09-30 | $-0.02 | $-0.02 | $-0.02 | 1 |
| 2027-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2028-03-31 | $-0.09 | $-0.09 | $-0.09 | 1 |
| 2028-06-30 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2028-09-30 | $-0.03 | $-0.03 | $-0.03 | 1 |
| 2028-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2029-12-31 | $-0.08 | $-0.08 | $-0.08 | 1 |
Frequently Asked Questions
What is the analyst consensus for CTKB?
The consensus among 3 analysts covering Cytek Biosciences, Inc. (CTKB) is Buy with an average price target of $5.13.
What is the highest price target for CTKB?
The highest price target for CTKB is $16.00, set by David Westenberg at Piper Sandler on 2022-08-17.
What is the lowest price target for CTKB?
The lowest price target for CTKB is $5.25, set by Matthew Sykes at Goldman Sachs on 2025-02-02.
How many analysts cover CTKB?
3 analysts have issued ratings for Cytek Biosciences, Inc. in the past 12 months.
Is CTKB a buy or sell right now?
Based on 3 analyst ratings, CTKB has a consensus rating of Buy (2.33/5) with a +29.7% upside to the consensus target of $5.13.
What are the earnings estimates for CTKB?
Analysts estimate CTKB will report EPS of $-0.21 for the period ending 2026-12-31, with revenue estimated at $208M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.